Chinese Hepatolgy ›› 2024, Vol. 29 ›› Issue (8): 900-904.
• Frontier, Exploration and Controversy • Previous Articles Next Articles
Received:2024-05-14
Online:2024-08-31
Published:2024-09-30
| [1] | 范建高,李小英.NAFLD更名MAFLD、MASLD:背景、异同、对策[J].中华肝病杂志,2023,31(8):789-792. |
| [2] | Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH[J].Transplantation,2019,103(1):e1-e13. |
| [3] | 张馨元,刘宇,王文玲等.非酒精性脂肪性肝病的诊断与评估[J].临床肝胆病杂志,2023,39(08):1780-1788. |
| [4] | 彭琳瑞,王柳,杨晓玲等.非酒精性脂肪性肝病的管理[J].中国实用内科杂志,2023,43(12):1028-1030. |
| [5] | Amangurbanova M, Huang DQ, Loomba R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD[J].Aliment Pharmacol Ther,2023,57(1):37-51. |
| [6] | Younossi ZM, Alqahtani SA, Alswat K, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease[J].J Hepatol,2024,80(3):419-430. |
| [7] | Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'[J].Liver Int,2020,40(6):1254-1261. |
| [8] | Carol M, Pérez-Guasch M, Solà E, et al. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life[J].PLoS One,2022,17(4):e0265153. |
| [9] | Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity[J].Liver Int,2021,41(10):2295-2307. |
| [10] | 赵冉,沙卫红.代谢相关脂肪性肝病的概念变更及其对临床实践的影响[J].实用医学杂志,2022,38(19):2390-2394. |
| [11] | 薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介[J].临床肝胆病杂志,2020,36(06):1224-1227. |
| [12] | Addison T. Observations on fatty degeneration of the liver[J]. Guys Hosp Rep, 1836, 1(476): 485. |
| [13] | Rokitansky CA. Skizze der Größen und Formabweichungen der Leber[J]. Bruchstück Med Jahrb des kaisl, königl österr Staates,1839,Bd 29 oder neueste Folge Bd 20 Wien: 557. |
| [14] | P. B. Diseases of the liver//Pepper W, Starr L. A System of Practical Medicine[M]. Philadelphia, PA: Lea Brothers & Co, 1885: 1050. |
| [15] | Connor CL. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism[J]. Am J Pathol,1938,14(3):347-364. |
| [16] | Lonardo A, Leoni S, Alswat KA, et al. History of Nonalcoholic Fatty Liver Disease[J].Int J Mol Sci,2020,21(16):5888. |
| [17] | Schaffner F, Thaler H. Nonalcoholic fatty liver disease[J].Prog Liver Dis,1986,8:283-298. |
| [18] | Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus[J].Nat Rev Gastroenterol Hepatol,2017,14(1):32-42. |
| [19] | Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J].Mol Metab,2020,42:101092. |
| [20] | Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China[J].Hepatology,2020,71(5):1851-1864. doi:10.1002/hep.31150? |
| [21] | Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J].J Hepatol,2018,69(4):896-904. |
| [22] | Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed?[J]. Dig Dis,2005,23(1):72-82. |
| [23] | Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J].J Hepatol,2020,73(1):202-209. |
| [24] | Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol,2024, 29(1):101133. |
| [25] | Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J].Hepatology,2023, 78(6):1966-1986. |
| [26] | Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management ofnonalcoholic fatty liver disease: Practice guidance from the American Association forthe Study of Liver Diseases[J].Hepatology,2018,67:328-57. |
| [27] | European Association for the Study of The L, European Association for the Study Of D, European Association for the Study Of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64:1388-402. |
| [28] | Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists[J].J Hepatol,2021,74(5):1254-1256. |
| [29] | Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease[J].Mol Metab,2021,50:101143. |
| [30] | Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies[J].Cancers (Basel),2022,15(1):23. |
| [31] | Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J].Liver Int,2020,40(9):2082-2089. |
| [32] | Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J].Liver Int,2020,40(12):3018-3030. |
| [33] | 陆伦根,尤红,谢渭芬等.肝纤维化诊断及治疗共识(2019年)[J].胃肠病学,2019,24(09):546-556. |
| [34] | Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD[J].Clin Gastroenterol Hepatol,2021,19(10):2172-2181.e6. |
| [35] | Kwon SY, Park J, Park SH, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease[J].Sci Rep,2023,13(1):1796. |
| [36] | Han E, Chun HS, Lee YH, et al. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study[J].J Gastroenterol Hepatol,2023,38(9):1598-1609. |
| [37] | Méndez-Sánchez N, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience[J].J Hepatol,2021,75(1):221-222. |
| [38] | Clayton M, Fabrellas N, Luo J, et al. From NAFLD to MAFLD: Nurse and allied health perspective[J].Liver Int,2021,41(4):683-691. |
| [39] | Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J].J Hepatol,2021,75(2):454-461. |
| [40] | Shaltout I, Alkandari H, Fouad Y, Hamed AE. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease[J].J Hepatol,2022,76(3):739-740. |
| [41] | Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease[J].Lancet Gastroenterol Hepatol,2021,6(1):65-72. |
| [42] | Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J].Hepatol Int,2020,14(6):889-919. |
| [43] | Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa[J]. Lancet Gastroenterol Hepatol,2021,6(1):57-64. |
| [44] | Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology[J].Hepatology,2021, 73(3):1194-1198. |
| [45] | Duseja A, Taneja S. Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease?- Not Only Premature But Also Confusing[J]. J Clin Exp Hepatol,2021,11(2):278-279. |
| [46] | Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2020,5(8):739-752. |
| [47] | Ng C, Chan K, Ou K, et al.IDDF2022-ABS-0132 Mafld and nafld in lean individuals. A prospective analysis of 12,505 lean individuals[J].Gut, 2022,71:A50.. |
| [48] | Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical[J].J Hepatol,2024, 80(2):e76-e77. |
| [49] | De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD[J].J Hepatol,2024,80(2):e61-e62. |
| [50] | Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD[J].J Hepatol,2024,80(2):e62-e64. |
| [51] | Sanal MG. Is the change from NAFLD to MASLD driven by political correctness?[J].J Hepatol,2024,80(2):e74-e76. |
| [52] | Cusi K, Younossi Z, Roden M. From NAFLD to MASLD: Promise and pitfalls of a new definition ?[J].Hepatology,2024,79(2):E13-E15. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
